Metallic radionuclides for radioimmunotherapy

Radioimmunotherapy of Cancer

Volumn , Issue , 2000, Pages 57-79

  Fritzberg, Alan R ^a   Meares, Claude F ^b  

^a Poniard Pharmaceuticals Inc   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85037665031     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (98)

1. Fritzberg AR, Wessels BW. Therapeutic radionuclides. In: Wagner HN, Szabo Z, Buchanan J, eds. Principles of Nuclear Medicine, 2nd ed. Philadelphia: W.B. Saunders Company, 1995:229-234.
2. Volkert WA, Goeckeler WF, Ehrhardt GJ, Ketring AR. Therapeutic radionuclides: production and decay property considerations. J Nucl Med 1991; 32:174-185.
3. Mausner LF, Srivastava SC. Selection of radionuclides for radioimmunotherapy. Med Phys 1993; 19:503-509.
4. Wessels BW, Rogus RD. Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies. Med Phys 1984; 11:638-645.
5. Meares CF, Goodwin DA, Leung CS, Girgis AY, Silvester DJ, Nunn AD, Lavender PL. Covalent attachment of metal chelates to proteins: the stability in vivo and in vitro of the conjugate of albumin with a chelate of 111-indium. Proc Natl Acad Sci USA 1976; 73:3803-3806.
6. Meares CF, McCall MJ, Reardan DT, Goodwin DA, Diamanti CI, McTigue M. Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal Biochem 1984; 142:68-78.
7. Brechbiel MW, Gansow OA, Atcher RW. Synthesis of 1-(p-isothiocynatobenzyl)-derivatives of DTPA and EDTA. Antibody labeling and tumor imaging studies. Inorg Chem 1986; 25:2772-2778.
8. Yeh SM, Sherman DG, Meares CF. A new route to “bifunctional” chelating agents: conversion of amino acids to analogs of ethylenedinitroilotetraacetic acid. Anal Biochem 1979; 100:152-159.
9. Sundberg MW, Meares CF, Goodwin DA, Diamanti CI. Selective binding of metal ions to macromolecules using bifunctional analogs of EDTA. J Med Chem 1974; 17:1304-1307.
10. Roselli M, Schlom J, Gansow OA, Raubitschek A, Mirzadeh S, Brechbiel MW, Colcher D. Comparative biodistributions of yttrium and indium-labeled monoclonal antibody B72.3 in athymic nude mice bearing human colon carcinoma xenografts. J Nucl Med 1989; 30:672-682.
11. Deshpande SV, Subramanian R, McCall MJ, DeNardo SJ, DeNardo GL, Meares CF. Metabolism of indium chelates attached to monoclonal antibody: minimal transchelation of indium from Benzyl-EDTA chelate in vivo. J Nucl Med 1990; 31:218-224.
12. Meares CF, Moi MK, Diril H, Kukis DL, McCall MJ, Deshpande SV, DeNardo SJ, Snook D, Epenetos AA. Macrocyclic chelates of radiometals for diagnosis and therapy. Br J Cancer 1990; 62(suppl):21-26.
13. Moerlein SM, Welch MJ, Raymond KN, Weitl FL. Tricatecholamide analogs of enterobactin as gallium-and indium-binding radiopharmaceuticals. J Nucl Med 1981; 22:710-719.
14. Hunt FC. Potential radiopharmaceuticals for the diagnosis of biliary atresia and neonatal hepatitis: EHPG and HBED chelates of 67Ga and 111In. Nucl Med Biol 1988; 15:659-664.
15. Mathias CJ, Sun Y, Welch MJ, Green MA, Thomas JA, Wade KR, Martell AE. Targeting radiopharmaceuticals: comparative biodistribution studies of gallium and indium complexes of multidentate ligands. Nucl Med Biol 1988; 15:69-81.
16. Pearson RG. Hard and soft acids and bases. J Am Chem Soc 1963; 85:3533-3539.
17. Hayes RL, Carlton JE, Byrd BL. Bone scanning with gallium-68: a carrier effect. J Nucl Med 1965; 6:605-610.
18. Weiner RE, Thakur ML, Goodman M, Hoffer PB. Relative stability of In-111 and Ga-67 desferrioxamine and human transferrin complexes. In: Radiopharmaceuticals II. New York: Society of Nuclear Medicine, 1979:331-340.
19. Green MA, Welch MJ, Mathias CJ, Fox KAA, Knabb RM, Huffman JC. Gallium-68 1,1,1-tris(5-methoxysalicylaldiminomethyl)ethane: a potential tracer for evaluation of regional myocardial blood flow. J Nucl Med 1985; 26:170-180.
20. Broan CJ, Cox JPL, Craig AS, Kataky R, Parker D, Harrison A, Randall AM, Ferguson G. Structure and solution stability of indium and gallium complexes of 1,4,7-triazacyclononanetriacetate and of yttrium complexes of 1,4,7,10-tetraazacyclododecanetetraacetate and related ligands: kinetically stable complexes for use in imaging and radioimmunotherapy. X-ray molecular structure of the indium and gallium complexes of 1,4,7-triazacyclononane-1,4,7-triacetic acid. J Chem Soc Perkin Trans 1991; 2:87-91.
21. Clarke ET, Martell AE. Stabilities of trivalent metal ion complexes of the tetraacetate derivatives of 12-, 13-and 14-membered tetraazamacrocycles. Inorg Chim Acta 1991; 190:37-46.
22. Wagner SJ, Welch MJ. Gallium-68 labeling of albumin and albumin microspheres. J Nucl Med 1979; 20:428-433.
23. Yokohama A, Ohmomo Y, Horiuchi K, Saji R, Tanaka H, Yamamoto K, Ishii Y, Torizuka K. Desferrioxamine, a promising bifunctional chelating agent for labeling proteins with gallium: Ga-67 DF-HSA. J Nucl Med 1982; 23:909-914.
24. Janoki AG, Harwig JF, Wolf W. Studies on high specific activity labeling of proteins using bifunctional chelates. Nucl Med Biol 1982; 1:689-692.
25. Larson SM, Allen DR, Ramsey JS, Grunbaum Z. Kinetics of binding of carrier-free Ga-67 to human transferrin. J Nucl Med 1978; 19:1245-1249.
26. Wike JS, Guyer CE, Ramey DW, Phillips BP. Chemistry for commercial scale production of yttrium-90 for medical research. Appl Radiat Isot 1990; 41:861.
27. Dietz ML, Horwitz EP. Improved chemistry for the production of yttrium-90 for medical applications. Appl Radiat Isot 1992; 43:1093-1101.
28. Rowlinson G, Snook D, Stewart S, Epenetos AA. Intravenous EDTA to reduce bone uptake of Y-90 following Y-90 labeled antibody administration. Br J Cancer 1989; 59:322-328.
29. Moi MK, Meares CF, DeNardo SJ. The peptide way to macrocyclic bifunctional chelating agents: Synthesis of 2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-NN’, N’, N -tetraacetic acid and study of its yttrium (III) complex. J Am Chem Soc 1988; 110:6266-6267.
30. Kozak RW, Raubitschek A, Mirzadeh S, Brechbiel MW, Junghaus R, Gansow OA, Waldmann TA. Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity. Cancer Res 1989; 49:2639-2644.
31. Loncin E, Desreux MF, Merciny JF. Coordination of lanthanides by two polyamino polycarboxylic macrocycles: formation of highly stable lanthanide complexes. Inorg Chem 1986; 25:2646-2648.
32. Deshpande SY, DeNardo SJ, Kukis DL, McCall ML, DeNardo GL, Meares CF. Yttrium-90 labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent. J Nucl Med 1990; 31:473-479.
33. Watanabe N, Goodwin DA, Meares CF, et al. Immunogenicity in rabbits and mice of an antibody-chelate conjugate: comparison of (s) and (R) macrocyclic enantiomers and an acyclic chelating agent. Cancer Res 1994; 54:1049-1054.
34. Kosmas C, Snook D, Gooden CS, et al. Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy. Cancer Res 1992; 52:904-911.
35. Kosmas C, Maraveyas A, Gooden CS, Snook D, Epenetos AA. Anti-chelate antibodies after intraperitoneal yttrium-90-labeled monoclonal antibody immunoconjugates for ovarian cancer therapy. J Nucl Med 1995; 36:746-753.
36. Camera L, Kinuya S, Garmestani K, Wu C, Brechbiel MW, Pai LH, McMurry TJ, Ganson OA, Pastan I, Paik CH, Carrasquillo JA. Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies. J Nucl Med 1994; 35:882-889.
37. Kobayashi H, WU C, Yoo TM, Sun B-F, Drumm D, Pastan I, Paik CH, Gansow OA, Carrasquillo JA, Brechbiel MW. Evaluation of the in vivo biodistribution of yttrium-labeled isomers of CHX-DTPA-conjugated monoclonal antibodies. J Nucl Med 1998; 39:829-836.
38. DeNardo SJ, Kukis DL, Miers LA, Winthrop MD, Kroger LA, Salako Q, Shen S, Lamborn KR, Gumerlock PH, Meares CF, DeNardo GL. Yttrium-90-DOTA-peptide chimeric L6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts. J Nucl Med 1998; 39:842-849.
39. Li M, Meares CF. Synthesis, metal chelate stability studies, and enzyme digestion of A peptide-linked DOTA derivative and its corresponding radiolabeled immunoconjugates. Bioconj Chem 1993; 4:275-283.
40. DeNardo SJ, Kukis DL, Kroger LA, O’Donnell RT, Lamborn KR, Miers LA, De Nardo DG, Meares CF, DeNardo GL. Synergy of taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. Proc Natl Acad Sci USA 1997; 94:4000-4004.
41. Moi MK, Meares CF, McCall MJ, Cole WC, DeNardo SJ. Copper chelates as probes of biological systems: stable copper complexes with a macrocyclic bifunctional chelating agent. Anal Biochem 1985; 148:249-253.
42. Green MA, Mathias CJ, Welch MJ, McGuire AH, Perry D, Fernandez-Rubio F, Perlmutter JS, Raichle ME, Bergman SR. Copper-62-labeled pyruvaldehyde bis(N-4-methylthiosemicarbazonato)copper(II): synthesis and evaluation as a positron emission tomography tracer for cerebral and myocardial perfusion. J Nucl Med 1990; 31:1989-1996.
43. Anderson CJ, Connett JM, Schwarz SW, Rocque PA, Guo LW, Philpott GW, Zinn KR, Meares CF, Welch MJ. Copper-64-labeled antibodies for PET imaging. J Nucl Med 1992; 33:1685-1691.
44. Connett JM, Anderson CJ, Guo L-W, Schwarz SW, Zinn KR, Rogers BE, Siegel BA, Philpott GW, Welch MJ. Radioimmunotherapy with a 64Cu-labeled monoclonal antibody: a comparison with 67Cu. Proc Natl Acad Sci USA 1996; 93:6814-6818.
45. Zinn KR, Chaudhuri TR, Cheng TP, Meyer WA, Morris JS. Production of no-carrier added 64Cu from zinc metal irradiated under boron shielding. Cancer 1994; 73:774-778.
46. McCarthy DW, Shefer RE, Klinkowstein RE, Bass LA, Margeneau WH, Cutler CS, Anderson CJ, Welch MJ. Efficient production of high specific activity 64Cu using a biomedical cyclotron. Nucl Med Biol 1997; 24:35-43.
47. Mirzadeh S, Mausner LF, Srivastava SC. Production of no-carrier added 67Cu. Appl Radiat Isot 1986; 37:29.
48. Troutner DE. Chemical and physical properties of radionuclides. Int J Radiat Appl Instrum Part B 1987; 14:171-176.
49. Ringborn A. Complexation in Analytical Chemistry. New York: Interscience, 1963.
50. Lau SJ, Sarkar B. Ternary coordination complex between human serum albumin, copper (II), and L-histidine. J Biol Chem 1971; 246:5938-5943.
51. White A, Handler P, Smith EL. Principles of Biochemistry 4th ed. New York: McGraw-Hill, 1968:711.
52. Studer M, Kaden TA, Maecke HR. Reactivity studies of the pendant carboxylic group in a macrocyclic Cu2 complex towards amide formation and its use as a protein-labeling agent. Helv Chim Acta 1990; 73:149-153.
53. Franz J, Freeman GM, Barefield EK, Volkert WA, Ehrhardt GJ, Holmes RA. Labeling of antibodies with 64Cu using a conjugate containing a macrocyclic amine chelating agent. Nucl Med Biol 1987; 14:479-484.
54. Deshpande SV, DeNardo SJ, Meares CF, McCall MJ, Adams GP, Moi K, DeNardo GL. Copper-67-labeled monoclonal antibody Lym-1, a potential radiopharmaceutical for cancer therapy: labeling and biodistribution in RAJI tumored mice. J Nucl Med 1988; 29:217-225.
55. DeNardo GL, DeNardo SJ, Meares CF, Kukis D, Moody DC, Deshpande SV. Pharmacokinetics of copper-67 conjugated Lym-1, a potential therapeutic radioimmunoconjugate, in mice and in patients with lymphoma. Antibody Immunoconj Radiopharm 1991; 4:777-785.
56. Morphy JR, Parker D, Kataky R, Eaton MAW, Millican AT, Alexander R, Harrison A, Walker C. Towards tumour targeting with copper-radiolabeled macrocycle-antibody conjugates: synthesis, antibody linkage, and complexation behaviour. J Chem Soc Perkin Trans 1990; 2:573-585.
57. Cole WC, DeNardo SJ, Meares CF, McCall MJ, DeNardo GL, Epstein AL, O’Brien HA, Moi MK. Comparative serum stability of radiochelates for antibody radiopharmaceuticals. J Nucl Med 1987; 28:83-90.
58. Kukis DL, Diril H, Greiner DP, DeNardo SJ, DeNardo GL, Salako QA, Meares CF. A comparative study of copper-67 radiolabeling and kinetic stabilities of antibodymacrocyclic chelate conjugates. Cancer 1994; 73(suppl):779-786.
59. O’Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with b-emitting radionuclides. J Nucl Med 1995; 36:1902-1909.
60. Jia W, Ehrhardt GJ. Progress toward enhanced specific activity Re-186 using inorganic Szilard-Chalmers methods. In: Nicolini M, Bandoli G, Mazzi U, eds. Technetium and Rhenium in Chemistry and Nuclear Medicine 4. Padova, Italy: SGE Editoriali, 1995:379-381.
61. Blumer M, Ehrhardt GJ, Su F-M. Experience with aluminum perrhenate targets for production of Re-186 and Re-188. J Nucl Med 1994; 35:242. Abstract.
62. Ehrhardt GJ, Ketring AR, Liang Q, Miller RA, Holmes RA, Wolfangel RG. Refinement of the peroxide process for making W-188/Re/188 and Mo-99/Tc-99m gel radioisotope generators for nuclear medicine. In: Nicolini M, Bandoli G, Mazzi U, eds. Technetium and Rhenium in Chemistry and Nuclear Medicine 4. Padova, Italy: SGE Editoriali, 1995:313-317.
63. Knapp FF Jr, Mirzadeh S, Beets AL, Sharket R, Griffiths G, Juweid M, Goldenberg DM. Curie-scale tungsten-188/rhenium-188 generators for routine clinical applications. In: Nicolini M, Bandoli G, Mazzi U, eds. Technetium and Rhenium in Chemistry and Nuclear Medicine 4. Padova, Italy: SGE Editoriali, 1995:319-323.
64. Deutsch EA, Libson K, Vanderheyden J-L, Ketring AR, Maxon HR. The chemistry of rhenium and technetium as related to the use of isotopes of these elements in therapeutic and diagnostic nuclear medicine. Nucl Med Biol 1986; 13:465-477.
65. Jones AG, Davison A. The relevance of basic technetium chemistry to nuclear medicine. J Nucl Med 1982; 23:1041-1043.
66. Davison A, Jones A, Orvig C, Sohn MG. A new class of oxotechnetium(5)chelate complexes containing a TcON2S2 core. Inorg Chem 1981; 20:1629-1632.
67. Rao TN, Adhikesavalu D, Camerman A, Fritzberg AR. Technetium(V) and rhenium(V) complexes of 2,3-bis(mercaptoacetamido)-propanoate. Chelate ring stereochemistry and influence on chemical and biological properties. J Am Chem Soc 1990; 112:5798-5804.
68. Griffiths GL, Goldenberg DM, Diril H, Hansen HJ. Technetium-99m, rhenium-186, and rhenium-188 direct-labeled antibodies. Cancer 1994; 73:761-768.
69. John E, Thakur ML, DeFulvio J, McDevitt MR, Damjanov I. Rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: preparation and evaluation. J Nucl Med 1992; 34:260-267.
70. Griffiths GL, Goldenberg DM, Jones AL, Hansen HJ. Radiolabeling of monoclonal antibodies and fragments with technetium and rhenium. Bioconj Chem 1992; 3:91-99.
71. Quadri SM, Wessels BW. Radiolabeled biomolecules with 186Re: potential for radioimmunotherapy. Nucl Med Biol 1986; 13:447-451.
72. Fritzberg AR, Nunn AD. Radio HPLC application to organics and metal chelate chemistry. In: Wieland D, Tobes M, Manger T, eds. Analytical and Chromatographic Techniques in Radiopharmaceutical Chemistry. Los Angeles: Springer-Verlag, 1985:183-212.
73. Fritzberg AR, Abrams PG, Beaumier PL, Kasina S, Morgan AC, Rao TN, Reno JM, Sanderson JA, Srinivasan A, Wilbur DS, Vanderheyden, J-L. Specific and stable labeling of antibodies with technetium-99m using a diamide dimercaptide (N2S2) chelating agent. Proc Natl Acad Sci USA 1988; 85:4025-4029.
74. Fritzberg AR, Vanderheyden J-L, Morgan AC, Schroff RW, Abrams PG. Rhenium-186/-188 labeled antibodies for radioimmunotherapy. In: Nicolini M, Bandoli G, Mazzi U, eds. Technetium and Rhenium in Chemistry and Nuclear Medicine 3. Verona, Italy: Cortina International, 1990:615-622.
75. Su F-M, Lyen L, Breitz HB, Weiden PL, Fritzberg AR. 186Rhenium Mag2GABA antibody radiolabeling. In: Nicolini M, Bandoli G, Mazzi U, eds. Technetium and Rhenium in Chemistry and Nuclear Medicine 4. Padova, Italy: SGE Editoriali, 1995: 511-517.
76. Visser GWM, Gerretsen M, Herscheid JDM, Snow GB, van Dongen G. Labeling of monoclonal antibodies with rhenium-186 using the MAG3 chelate for radioimmunotherapy of cancer: a technical protocol. J Nucl Med 1993; 34:1953-1963.
77. Ram S, Buchsbaum DJ. A peptide-based bifunctional chelating agent for 99mTc-and 186Re-labeling of monoclonal antibodies. Cancer 1994; 73:769-773.
78. Vanderheyden J-L, Su F-M, Venkatesan P, Beaumier P, Bugaj J, Fritzberg A. The chemistry of rhenium-186 labeled antibodies and F(ab’)2 fragments for RIT in animals and man. J Nucl Med 1990; 31:823. Abstract.
79. Su F-M, Axworthy D, Galster J, Weiden P, Vanderheyden J-L, Fritzberg AR. Characterization of patients urinary catabolites from Re-186 radiolabeled monoclonal antibodies and fragments. J Nucl Med 1990; 31:823. Abstract.
80. Srinivasan A, Kasina S, Fitzner JN, Gustavson LG, Reno JM, Rao TN, Sanderson JA, Gray MA, Axworthy D, Fritzberg AR. Modified bifunctional amide thiolate ligands: enhanced utility of Tc-99m Fab for radioimmunodetection. J Nucl Med 1990; 31:747. Abstract.
81. Su F-M, Axworthy DB, Vanderheyden J-L, Srinivasan A, Fitzner J, Galster J, Kasina S, Reno J, Beaumier P, Fritzberg AR. Evaluation of a cleavable N3S-hydroxyl ester ligand for improved targeting of rhenium-186 antibodies. J Nucl Med 1991; 32:Abstract
82. Beaumier P, Venkatesan P, Vanderheyden J-L, Burgua WD, Kunz LL, Fritzberg AR, Abrams PG, Morgan AC Jr. 186Re radioimmunotherapy of small cell lung carcinoma xenografts in nude mice. Cancer Res 1991; 51:676-681.
83. Najafi A, Alauddin MM, Sosa A, Ma GQ, Chen DCP, Epstein AL, Siegel ME. The evaluation of 186Re-labeled antibodies using N2S4 chelate in vitro and in vivo using tumor-bearing nude mice. Nucl Med Biol 1992; 19:205-212.
84. Gerretsen M, Visser GWM, van Walsum M, Meijer CJLM, Snow GB, van Dongen GAMS. 186Re-labeled monoclonal antibody E48 immunoglobulin G-mediated therapy of human head and neck squamous cell carcinoma xenografts. Cancer Res 1993; 53:3524-3529.
85. Zalutsky MR, Bigner DD. Radioimmunotherapy with a-particle emitting radioimmunoconjugates. Acta Oncol 1996; 35:373-379.
86. Zalutsky MR, Schuster JM, Garg PK, Archer GE Jr., Dewhirst MW, Bigner DD. Two approaches for enhancing radioimmunotherapy: a emitters and hyperthermia. Recent Results Cancer Res 1996; 141:101-122.
87. Huneke RB, Pippin CG, Squire RA, Brechbiel MW, Gansow OA, Strand M. Effective a-particle-mediated radioimmunotherapy of murine leukemia. Cancer Res 1992; 52:5818-5821.
88. Rotmensch J, Whitlock JL, Schwartz JL, Hines JJ, Reba RC, Harper PV. In vitro and in vivo studies on the development of the a-emitting radionuclide bismuth 212 for intraperitoneal use against microscopic ovarian carcinoma. Am J Obstet Gynecol 1997; 176:833-841.
89. Zalutsky MR, McLendon RE, Garg PK, Archer GE, Schuster JM, Bigner DD. Radioimmunotherapy of neoplastic meningitis in rats using an a-particle-emitting immunoconjugate. Cancer Res 1994; 54:4719-4725.
90. Beyer GJ, Offord RE, Kunz G, Jones RMI, Ravn U, Aleksandrova Y, Werlen RC, Macke H, Lindroos M, Jahn S, Tengblad D. Biokinetics of monoclonal antibodies labeled with radio-lanthanides and 225-Ac in xenografted nude mice. Proc. 12th Int Symp Radiopharm Chem, Uppsala, Sweden, 1997:529-530.
91. Scheinberg DA. Presentation of Phase I clinical study in leukemia patients. AAAS, 163rd Meeting, Seattle WA, 1997.
92. Wu C, Brechbiel MW, Gansow OA. An improved generator for the production of 213Bi from 225Ac. Radiochim Acta 1997; 79:141-144.
93. Boll RA, Mirzadeh S, Kennel SJ. Optimizations of radiolabeling of immunoproteins with 213Bi. Radiochim Acta 1997; 79:145-149.
94. Atcher RW, Friedman AM, Hines JJ. An improved generator for the production of 212Pb and 212Bi from 224Ra. Appl Radiat Isot 1988; 39:283-286.
95. Kumar K, Magerstädt M, Gansow OA. Lead (II) and bismuth (III) complexes of the polyazacycloalkane-N-acetic acids nota, dota, and teta. Chem Comm 1989; 145-146.
96. Pippin CG, McMurry TJ, Brechbiel MW, McDonald M, Lambrecht R, Milenic D, Roselli M, Colcher D, Gansow OA. Lead (II) complexes of 1,4,7,10-tetraazacyclododecane-N, N’, N’, N -tetraacetate: solution chemistry and application to tumor localization with 203Pb labeled monoclonal antibodies. Inorg Chim Acta 1995; 239: 43-51.
97. Mirzadeh S, Kumar K, Gansow OA. The chemical fate of 212Bi-DOTA produced by ß-decay of 212Pb(DOTA)2. Radiochim Acta 1993; 60:1-10.
98. Horak E, Hartmann F, Garmestani G, Wu C, Brechbiel M, Gansow OA, Landolfi NF, Waldmann TA. Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1. J Nucl Med 1987; 38:1944-1950.